Effect of scaling on levels of interleukin 1-beta and clinical periodontal parameters among e-cigarette users and non-smokers: A prospective study.

ABSTRACT

INTRODUCTION: This cohort study aimed to compare the effect of ultrasonic scaling on the expression of IL-1ß in the gingival crevicular fluid (GCF) among ENDS users and non-smokers (NS) with gingivitis. METHODS: Self-reported current electronic nicotine delivery system (ENDS) users and NS with generalized gingivitis were included in this study. All the patients underwent scaling at the baseline visit (T0). Clinical measures, periodontal parameters [probing depth (PD), plaque index (PI), and bleeding on probing (BOP)], and GCF IL-1ß were measured at T0, after 1 week (T1) and after 3 weeks (T2). Wilcoxon signed rank test was used to assess the changes in the periodontal measurements and IL-1ß levels at different time points and Mann-Whitney U Test was used to compare the two groups. RESULTS: A total of 38 individuals (18 NS and 20 ENDS users) participated in the study. The PD was significantly higher in ENDS users than in NS at baseline. However, the PI and BOP were similar in all groups at baseline. At T1, the PI was significantly lower for NS than for ENDS users (p=0.045). At T2, there were no significant differences in any of the parameters assessed between the two groups. For ENDS users, BOP was significantly lower at T1 than at baseline. For NS, the BOP at T1 and T2 and the PI at T1 were significantly lower than at baseline. There was no difference in the GCF IL-1ß levels in NS and ENDS users at baseline, T1, and T2. At T2, there was a significant reduction in IL-1ß (p<0.05) than at baseline in both groups. CONCLUSIONS: Both ENDS users and NS with gingivitis responded similarly to scaling. GCF IL-1ß levels were significantly higher at baseline (p<0.05) compared with their levels at T1 and T2 for both the groups. CLINICAL TRIAL REGISTRATION The study was registered on the official website of ClinicalTrials.gov. IDENTIFIER ID NCT05745324.